RET溶剂前沿突变介导选择性RET抑制剂获得性耐药
该研究分析了RET融合阳性NSCLC和RET突变阳性MTC患者在接受selpercatinib初始响应后进展的循环肿瘤DNA和组织,发现RET G810溶剂前沿突变(G810R/S/C)在临床耐药出现前即可检出,且存在瘤内和瘤间异质性。 preclinical模型证实这些突变导致selpercatinib及多激酶抑制剂活性丧失。
要点
- RET G810溶剂前沿突变是selpercatinib获得性耐药的 recurrent 机制。
- 耐药突变可在临床进展前通过ctDNA检测发现。
- G810突变导致selpercatinib及多激酶抑制剂活性丧失。
核心结论
- RET G810溶剂前沿突变是首个描述的选择性RET抑制剂selpercatinib的复发性耐药机制。
研究设计与样本
- 分析RET融合阳性NSCLC和RET突变阳性MTC患者进展后的循环肿瘤DNA和组织。
- 使用CCDC6-RET融合阳性NSCLC患者来源异种移植模型进行临床前耐药建模。
- 通过酶和细胞实验评估抗RET多激酶抑制剂及选择性RET TKIs的抑制活性。
主要发现
- 一例KIF5B-RET NSCLC患者对selpercatinib显著响应后,ctDNA出现RET G810R、G810S和G810C突变。
- 尸检显示多部位存在含G810S、G810R和G810C的不同亚克隆,提示趋同进化。
- 第二例CCDC6-RET NSCLC肿瘤组织及额外NSCLC和MTC患者血浆中检出RET G810获得性突变。
- CCDC6-RET患者来源异种移植模型中出现RET G810R突变。
- 结构建模预测突变空间阻碍selpercatinib结合,体外实验证实抗RET多激酶抑制剂和选择性RET TKIs活性丧失。
临床怎么用
- 对selpercatinib治疗进展的患者,可通过ctDNA检测RET G810溶剂前沿突变。
- 开发针对G810突变且保持抗RET门控突变活性的强效抑制剂可能是克服耐药的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and RET-mutated medullary thyroid cancer (MTC). However, the mechanisms of resistance to these agents have not yet been described. METHODS: Analysis was performed of circulating tumor DNA and tissue in patients with RET fusion-positive NSCLC and RET-mutation positive MTC who developed disease progression after an initial response to selpercatinib. Acquired resistance was modeled preclinically using a CCDC6-RET fusion-positive NSCLC patient-derived xenograft. The inhibitory activity of anti-RET multikinase inhibitors and selective RET TKIs was evaluated in enzyme and cell-based assays. RESULTS: After a dramatic initial response to selpercatinib in a patient with KIF5B-RET NSCLC, analysis of circulating tumor DNA revealed emergence of RET G810R, G810S, and G810C mutations in the RET solvent front before the emergence of clinical resistance. Postmortem biopsy studies reported intratumor and intertumor heterogeneity with distinct disease subclones containing G810S, G810R, and G810C mutations in multiple disease sites indicative of convergent evolution on the G810 residue resulting in a common mechanism of resistance. Acquired mutations in RET G810 were identified in tumor tissue from a second patient with CCDC6-RET fusion-positive NSCLC and in plasma from patients with additional RET fusion-positive NSCLC and RET-mutant MTC progressing on an ongoing phase 1 and 2 trial of selpercatinib. Preclinical studies reported the presence of RET G810R mutations in a CCDC6-RET patient-derived xenograft (from a patient with NSCLC) model of acquired resistance to selpercatinib. Structural modeling predicted that these mutations sterically hinder the binding of selpercatinib, and in vitro assays confirmed loss of activity for both anti-RET multikinase inhibitors and selective RET TKIs. CONCLUSIONS: RET G810 solvent front mutations represent the first described recurrent mechanism of resistance to selective RET inhibition with selpercatinib. Development of potent inhibitor of these mutations and maintaining activity against RET gatekeeper mutations could be an effective strategy to target resistance to selective RET inhibitors.
引用
- Solomon BJ, Tan L, Lin JJ, et al. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. J Thorac Oncol. 2020. PMID: 31988000. doi:10.1016/j.jtho.2020.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。